£37.0M
The Series C round was co-led by R42 Group and Atomico to support clinical trials for rare disease treatments.
Healx
Healx deploys artificial intelligence to discover new therapies for rare conditions.
£88.5MTotal raised
Healx is a clinical-stage biotechnology company that uses artificial intelligence to discover and develop treatments for rare diseases. Based in Cambridge, the organisation combines advanced drug discovery techniques with a growing clinical pipeline.
Categories
Founders
Tim Guilliams
CEO
Tim is the co-founder and CEO of Healx. He also serves as an Entrepreneurship Fellow at Cambridge Judge Business School and previously directed the Cambridge Rare Disease Network.
LinkedIn
David Brown
Chairman
David brings board-level and scientific experience from co-founding Healx and chairing ProFactor Pharma, alongside earlier trustee work at Antibiotic Research UK.
LinkedIn
Andreas Bender
Andreas is a founder of Healx and a professor for machine learning in medicine, bringing academic and advisory experience across life sciences and drug discovery.
LinkedInInvestors
- £37.0M
- £43.9M
- £7.7M
Funding history
£43.9M
The financing round was led by Atomico with participation from several returning and new investors.
£7.7M
Balderton Capital led the Series A round with participation from Amadeus Capital Partners and Jonathan Milner.